Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Genmab, Files IND for HuMax-CD20 to Treat Non-Hodgkin’s Lymphoma19 Dec 2003
Genmab, quarterly statement of shareholdings17 Dec 2003
Genmab, and Sanquin Collaborate to Improve Hemophilia Treatment16 Dec 2003
Genmab, Results of Genmab's HuMax-CD4 Phase II Psoriasis Study12 Dec 2003
Genmab, Genmab's HuMax-CD20 Shows Unique Properties8 Dec 2003
Genmab, Genmab’s HuMax-CD4 Achieves Positive Results in T-Cell Lymphoma Phase II Studies7 Dec 2003
Genmab, grant of warrants4 Dec 2003
Genmab, Articles of Association dated Dec. 4, 2003
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
4 Dec 2003
Genmab, and ACE BioSciences to Develop Product to Treat Fungal Infections17 Nov 2003
Genmab, financial calendar 200414 Nov 2003
Genmab, Passing of Extraordinary General Meeting in Genmab A/S - Grant of Warrants11 Nov 2003
Genmab, articles of association as per 11 November 200311 Nov 2003
  • Previous
  • 1
  • More pages
  • 145
  • 146
  • 147
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863